Abstract:In psychiatric disorders, common and rare genetic variants cause widespread dysfunction of cells and their interactions, especially in the prefrontal cortex, giving rise to psychiatric symptoms. To better understand these processes, we traced the effects of common and rare genetics, and cumulative disease risk scores, to their molecular footprints in human cortical single-cell types. We demonstrated that examining gene expression at single-exon resolution is crucial for understanding the cortical dysregulation associated with diagnosis and genetic risk derived from common variants. We then used disease risk scores to identify a core set of genes that serve as a footprint of common and rare variants in the cortex. Pathways enriched in these genes included dopamine regulation, circadian entrainment, and hormone regulation. Single-nuclei-RNA-sequencing pinpointed these enriched genes to excitatory cortical neurons. This study highlights the importance of studying sub-gene-level genetic architecture to classify psychiatric disorders based on biology rather than symptomatology, to identify novel targets for treatment development. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Protocols <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233860/pdf/jove-20-914.pdf> ### Funding Statement The Victorian Brain Bank tissue collection was supported by the National Health and Medical Research Council (NHMRC; Australia; grant number 566967) and the Cooperative Research Centre (CRC) for Mental Health and the Operational Infrastructure Support from the Victorian State Government. The New South Wales Brain Tissue Resource Centre at the University of Sydney was supported by the University of Sydney. Research reported in this publication was supported by the National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number NIAAA012725-15. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. Dr Knauer-Arloth was supported by the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #28063). Dr Matosin was supported by an Al and Val Rosenstrauss Fellowship from the Rebecca L Cooper Medical Research Foundation and grants from the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #26486) and the Rebecca L. Cooper Medical Research Foundation (#PG2020645). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of the Victorian Institute of Forensic Medicine gave ethical approval for this work. Ethics committee/IRB of the Human Ethics Committee of Melbourne Health gave ethical approval for this work. Ethics committee/IRB of the Central Institute of Mental Health Mannheim gave ethical approval for this work. Ethics committee/IRB of the University Hospital Bonn gave ethical approval for this work. Ethics committee/IRB of the Human Research Ethics Committees at the University of Wollongong gave ethical approval for this work. Ethics committee/IRB of the Ludwig-Maximilians-Universitaet Muenchen gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Expression data of dataset 1 in the present study are available online at GEO (GSE208338) and the genotypes are available upon reasonable request to the authors. Genes altered by rare coding variants from SCHEMA exome sequencing results in dataset 2 are available online at https://schema.broadinstitute.org/downloads. snRNA-seq data of dataset 3 in the present study are available online at GEO (GSE205642). <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205642> <https://drive.google.com/drive/folders/1JRyThjCwb7JFE6LdQQiAHwXQZFIO2o0V?usp=sharing> <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208338> <https://schema.broadinstitute.org/downloads>

BrainEXP-NPD: a database of transcriptomic profiles of human brains of six neuropsychiatric disorders

Commonality in Dysregulated Expression of Gene Sets in Cortical Brains of Individuals with Autism, Schizophrenia, and Bipolar Disorder

Single-cell atlas of transcriptomic vulnerability across multiple neurodegenerative and neuropsychiatric diseases

Variant-risk-exon interplay impacts circadian rhythm and dopamine signaling pathway in severe psychiatric disorders

Transcriptomic sex differences in postmortem brain samples from patients with psychiatric disorders

Neuroimmune Transcriptome Changes in Patient Brains of Psychiatric and Neurological Disorders.

Disrupted long-range gene regulations elucidate shared tissue-specific mechanisms of neuropsychiatric disorders

Cross-Species Analysis of Gene Expression and Function in Prefrontal Cortex, Hippocampus and Striatum.

A Comprehensive Evaluation of Cross-Omics Blood-Based Biomarkers for Neuropsychiatric Disorders

BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders

An Integrated Transcriptomic Analysis of Autism Spectrum Disorder

Gene Expression Analysis of Multiple Brain Regions in Major Depressive Disorder

Single-nucleus transcriptome-wide association study of human brain disorders

A Combined Analysis of Genome-Wide Expression Profiling of Bipolar Disorder in Human Prefrontal Cortex.

Transcriptome Profiling of Dysregulated GPCRs Reveals Overlapping Patterns across Psychiatric Disorders and Age-Disease Interactions

Sex-differential DNA Methylation and Associated Regulation Networks in Human Brain Implicated in the Sex-Biased Risks of Psychiatric Disorders

CommonMind Consortium provides transcriptomic and epigenomic data for Schizophrenia and Bipolar Disorder

Transcriptomics Analysis Reveals Shared Pathways in Peripheral Blood Mononuclear Cells and Brain Tissues of Patients With Schizophrenia

Prioritizing Genes Associated with Brain Disorders by Leveraging Enhancer-Promoter Interactions in Diverse Neural Cells and Tissues

Transcriptomic Causal Networks identified patterns of differential gene regulation in human brain from Schizophrenia cases versus controls

Transcriptomic pathology of neocortical microcircuit cell types across psychiatric disorders